How Investors Are Reacting To Royalty Pharma (RPRX) Expanding Oncology Royalties With Nuvalent Deal

Simply Wall St.12-17

Royalty Pharma recently acquired a pre-existing royalty interest in Nuvalent’s cancer drug candidates neladalkib and zidesamtinib for up to US$315,000,000, securing potential royalty streams through ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2592798953?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2025-12-17 05:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2592798953","market":"us","top_or_hot":-1,"title":"How Investors Are Reacting To Royalty Pharma (RPRX) Expanding Oncology Royalties With Nuvalent Deal","media":"Simply Wall St.","content":"<div>\n<p>Royalty Pharma recently acquired a pre-existing royalty interest in Nuvalent’s cancer drug candidates neladalkib and zidesamtinib for up to US$315,000,000, securing potential royalty streams through ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rprx/royalty-pharma/news/how-investors-are-reacting-to-royalty-pharma-rprx-expanding\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors Are Reacting To Royalty Pharma (RPRX) Expanding Oncology Royalties With Nuvalent Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors Are Reacting To Royalty Pharma (RPRX) Expanding Oncology Royalties With Nuvalent Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-17 05:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rprx/royalty-pharma/news/how-investors-are-reacting-to-royalty-pharma-rprx-expanding><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Royalty Pharma recently acquired a pre-existing royalty interest in Nuvalent’s cancer drug candidates neladalkib and zidesamtinib for up to US$315,000,000, securing potential royalty streams through ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rprx/royalty-pharma/news/how-investors-are-reacting-to-royalty-pharma-rprx-expanding\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rprx/royalty-pharma/news/how-investors-are-reacting-to-royalty-pharma-rprx-expanding","article_id":"2592798953","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rprx/royalty-pharma/news/how-investors-are-reacting-to-royalty-pharma-rprx-expanding","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2592798953","pubTimestamp":1765920253,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Royalty Pharma recently acquired a pre-existing royalty interest in Nuvalent’s cancer drug candidates neladalkib and zidesamtinib for up to US$315,000,000, securing potential royalty streams through about 2041–2042.\nThis move broadens Royalty Pharma’s exposure to next-generation lung cancer treatments targeting ALK and ROS1 mutations, underscoring its focus on late-stage oncology innovation.\nWe’ll now examine how this oncology-focused royalty acquisition could influence Royalty Pharma’s...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","NUVL":"Nuvalent, Inc.","BK4007":"制药","RPRX":"Royalty Pharma plc","ISBC":"投资者银行","BK4211":"区域性银行","BK4539":"次新股"},"translate_title":"投资者对Royalty Pharma(RPRX)通过Nuvalent交易扩大肿瘤特许权使用费有何反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RPRX":1.5,"NUVL":1.5,"ISBC":1.5},"content_text":"Royalty Pharma recently acquired a pre-existing royalty interest in Nuvalent’s cancer drug candidates neladalkib and zidesamtinib for up to US$315,000,000, securing potential royalty streams through about 2041–2042. This move broadens Royalty Pharma’s exposure to next-generation lung cancer treatments targeting ALK and ROS1 mutations, underscoring its focus on late-stage oncology innovation. We’ll now examine how this oncology-focused royalty acquisition could influence Royalty Pharma’s investment narrative and long-term portfolio outlook. The end of cancer? These 29 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.Royalty Pharma Investment Narrative RecapTo own Royalty Pharma, you need to believe in its model of turning a broad portfolio of biopharma royalties into durable cash flows, refreshed by new deals in high‑value areas like oncology. The Nuvalent royalty purchase fits that story by adding potential long‑duration cancer cash flows, but it does not alter the most immediate swing factors, which remain the Vertex Alyftrek royalty dispute and any pressure on margins from more intense competition for deals. Among recent developments, TD Cowen’s updated research, which reaffirmed a positive stance on Royalty Pharma and raised its price target to US$45.00, is most relevant here, as it explicitly cites the breadth of the company’s commercial and development‑stage royalty portfolio. That broader context helps frame the Nuvalent deal as part of an ongoing effort to extend portfolio duration and offset product‑specific risks such as patent cliffs and generic competition. Yet against this backdrop of new oncology royalties, investors should also be aware of how increasing competition for biopharma royalty assets could... Read the full narrative on Royalty Pharma (it's free!)Royalty Pharma's narrative projects $4.0 billion revenue and $922.7 million earnings by 2028. This requires 20.0% yearly revenue growth and an earnings decrease of about $77.3 million from $1.0 billion today.Uncover how Royalty Pharma's forecasts yield a $45.98 fair value, a 19% upside to its current price.Exploring Other PerspectivesRPRX 1-Year Stock Price Chart Four members of the Simply Wall St Community currently see fair value for Royalty Pharma between US$45.98 and US$172.05, showing how far opinions can spread. Set against this wide range, the risk that rising competition in royalty financing could compress returns and pressure margins is a key factor readers may want to weigh as they compare these different views.Explore 4 other fair value estimates on Royalty Pharma - why the stock might be worth just $45.98!Build Your Own Royalty Pharma NarrativeDisagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.A great starting point for your Royalty Pharma research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.Our free Royalty Pharma research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Royalty Pharma's overall financial health at a glance.Want Some Alternatives?Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:Find companies with promising cash flow potential yet trading below their fair value.AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.The latest GPUs need a type of rare earth metal called Dysprosium and there are only 33 companies in the world exploring or producing it. Find the list for free.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.The New Payments ETF Is Live on NASDAQ:Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.Explore how this launch could reshape portfoliosSponsored ContentNew: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2592798953","isCrawlerRequest":true}